phrykt

Yarrow Bioscience, Inc. (YARW): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of YARW were reported in the last 12 months. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

No YARW insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

YARW short interest

Moderate short interest. 5.3% of YARW shares are sold short: about 1 share in 19. Over the last 7 reports the number of shares short went up 1028%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 141,913 YARW shares were sold short, 5.3% of the shares outstanding, up 7.5% from the report before. At the average daily volume of 170,564 shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

5.32%Jul 31Oct 308.16%

Days to cover

1.0Jul 31Oct 301.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026141,9135.32%+8%170,5641.0
Oct 15, 2026131,9924.94%-30%101,6411.3
Sep 30, 2026189,5867.10%+50%158,3631.2
Sep 15, 2026126,5284.74%+124%170,9371.0
Aug 31, 202656,4992.12%+191%46,9171.2
Aug 14, 202619,4270.73%+54%17,3821.1
Jul 31, 202612,5820.04%-93%38,6571.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Yarrow Bioscience company events

Yarrow Bioscience filed 14 reports on Form 8-K in the last 12 months, 3 of them about an important change (control, listing). The latest was on Sep 14, 2026.

  1. Sep 14, 2026AgreementYarrow Bioscience, Inc. entered into an underwriting agreement with Jefferies LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC, as the representatives of the underwriters named therein, to issue and sell 5,769,231 shares of the Company’s common stock at a public offering price of $26.00… Filing
  2. Sep 10, 2026AnnouncementYarrow Bioscience, Inc., a Delaware corporation, made available the Company’s investor presentation to be used in general corporate communications and investor communications. Filing
  3. Aug 13, 2026ResultsAmended an earlier report. Released financial results. Filing
  4. Jul 30, 2026AnnouncementYarrow Bioscience, Inc. entered into an exchange agreement with a certain existing stockholder, pursuant to which the Stockholder agreed to exchange an aggregate of 133,290 shares of the Company’s common stock, par value $0.0001 per share, for pre-funded warrants to purchase an aggregate of 133,290… Filing
  5. Jul 28, 2026ControlTo the extent required by this Item, the information included under the heading “ Introductory Note ” and in Item 2.01 of this Current Report on Form 8-K is incorporated herein by reference. Filing
  6. Jul 21, 2026AnnouncementAt the special meeting in lieu of the annual meeting of VYNE stockholders on July 16, 2026, VYNE’s stockholders approved a proposal to amend the amended and restated certificate of incorporation of VYNE to effect a reverse stock split of issued and outstanding common stock of VYNE, par value… Filing
  7. Jul 20, 2026VoteReported shareholder vote results. Filing
  8. Jul 14, 2026AnnouncementShared information with investors. Filing
  9. Jul 10, 2026AnnouncementAs previously disclosed, on December 17, 2025, the Company entered into an Agreement and Plan of Merger and Reorganization (as amended, the “Merger Agreement”) with Yarrow Bioscience, Inc., a Delaware corporation, and Yellow Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of… Filing
  10. May 21, 2026AnnouncementShared information with investors. Filing
  11. Mar 11, 2026ListingAs previously disclosed in a Current Report on Form 8-K filed by VYNE Therapeutics Inc. on September 12, 2025, the Company received a notification from The Nasdaq Stock Market, LLC that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share… Filing
  12. Jan 30, 2026AgreementVYNE Therapeutics Inc., a Delaware corporation, Yarrow Merger Sub Corp., a Delaware corporation and a wholly-owned subsidiary of VYNE, and Yarrow Bioscience, Inc., a Delaware corporation, entered into an amendment to that certain Agreement and Plan of Merger and Reorganization, dated December 17… Filing
  13. Dec 17, 2025ControlTo the extent required by this Item, the information included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. Filing
  14. Dec 12, 2025VoteReported shareholder vote results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Yarrow Bioscience financials

Famous investors that hold YARW

3 of the 50 well-known investors we track reported holding YARW in their latest 13F filing. The largest position is Ken Griffin's, worth $6.7M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026297,361$6.7M0.0%New
George Soros · Soros Fund ManagementQ3 202612,000$270K0.0%New
Israel Englander · Millennium ManagementQ3 202610,785$243K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 18 filings named YARW in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Ameriprise Financial, Inc.13G8.6%
Nov 16, 2026Ameriprise Financial, Inc.13G8.6%
Nov 16, 2026ADAR1 Capital Management, LLC13G/A2.5%
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G/A3.0%
Nov 16, 2026Perceptive Advisors LLC13G/A10.0%
Nov 16, 2026RTW Fund Group GP, LLC13G/A9.9%
Nov 16, 2026venBio Global Strategic Fund V, L.P.13G/A10.0%
Nov 16, 2026ADAR1 Capital Management, LLC13G/A2.5%
Nov 16, 2026Perceptive Advisors LLC13G/A10.0%
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G/A3.0%
Nov 16, 2026RTW Fund Group GP, LLC13G/A9.9%
Nov 16, 2026venBio Global Strategic Fund V, L.P.13G/A10.0%
Nov 13, 2026Spruce Street Capital LP13G6.4%
Nov 13, 2026Spruce Street Capital LP13G6.4%
Nov 13, 2026Nantahala Capital Management, LLC13G/A0.5%
Nov 13, 2026Nantahala Capital Management, LLC13G/A0.5%
Oct 7, 2026Bellevue Group AG13G10.6%
Oct 7, 2026Bellevue Group AG13G10.6%

Questions about Yarrow Bioscience, Inc. (YARW) stock

Are YARW insiders buying or selling?

No YARW insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in YARW?

As of Oct 30, 2026, 141,913 YARW shares were sold short, 5.3% of the shares outstanding, up 7.5% from the report before. At the average daily volume of 170,564 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Which famous investors hold YARW?

3 of the 50 well-known investors we track reported YARW in their latest 13F filing, including Ken Griffin, George Soros, Israel Englander. The largest position is worth $6.7M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.